Welcome to our dedicated page for LakeShore Biopharma Co. SEC filings (Ticker: LSB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LakeShore Biopharma Co., Ltd (LSB) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the biotechnology and healthcare sector. LakeShore Biopharma files reports with the U.S. Securities and Exchange Commission, including annual reports on Form 20-F and current reports on Form 6-K, which cover financial performance, corporate actions, listing status, and material agreements.
For investors analyzing LakeShore Biopharma’s structure and corporate trajectory, recent Form 6-K filings are particularly relevant. One filing references a press release titled "LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting", documenting the suspension of trading of its ordinary shares and warrants on The Nasdaq Capital Market and the expected commencement of trading on the OTC Pink Open Market under the symbols LSBCF and LSBWF. This filing outlines Nasdaq’s determination based on non-compliance with the minimum bid price requirement and the related listing rules.
Another Form 6-K includes a press release titled "LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction" and an Agreement and Plan of Merger among LakeShore Biopharma, Oceanpine Skyline Inc., and Oceanpine Merger Sub Inc. This document provides the formal framework for the going-private transaction with Oceanpine-affiliated entities, following earlier disclosures of preliminary and revised non-binding proposals to acquire all outstanding ordinary shares not already owned by the proposing parties.
Through its SEC filings, LakeShore Biopharma also presents detailed financial information, including discussions of non-GAAP measures such as EBITDA, Adjusted EBITDA, and adjusted net income (loss), along with reconciliations to U.S. GAAP metrics. On this page, AI-powered tools can help readers quickly interpret lengthy filings, highlight key sections related to listing changes, merger agreements, and financial metrics, and make it easier to track the evolution of LakeShore Biopharma’s regulatory and corporate profile over time.
LakeShore Biopharma reports that the buyer group for its previously announced going‑private deal at $0.90 per share has sent a notice claiming a “Company Material Adverse Effect” under the merger agreement.
The claim is based on arbitral awards that created an approximate RMB576,500,000 financial liability. Citing this, the buyer group asserts it has the right not to consummate the merger and says it will not attend or vote at the extraordinary general meeting that was scheduled for February 12, 2026. In response, the company has postponed the meeting indefinitely and will disregard any previously submitted proxy cards, while it reviews the buyer group’s position and its own options.
LakeShore Biopharma’s buyer group has determined that recent arbitration awards mean its planned merger cannot proceed on current terms. Three awards from the Kaifeng Arbitration Commission require certain PRC subsidiaries to pay about RMB576.5 million, which the group believes causes a “Company Material Adverse Effect” under the merger agreement.
Because this condition to closing can no longer be met, the buyer group has notified the company it will not proceed with closing and its members will not attend or vote at the February 12, 2026 extraordinary general meeting. The group, however, plans to discuss potential amended transaction terms with the issuer.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.
LakeShore Biopharma (LSB) filed a Form 6‑K announcing it has entered into a definitive agreement for a going‑private transaction. The filing furnishes two exhibits: a press release and an Agreement and Plan of Merger dated November 4, 2025.
The merger agreement is among LakeShore Biopharma Co., Ltd, Oceanpine Skyline Inc., and Oceanpine Merger Sub Inc. The 6‑K provides notice of the agreement and includes the full documents as exhibits.
LakeShore Biopharma Co., Ltd filed a Form 6-K as a foreign private issuer, mainly to furnish a press release about its stock trading status. The company announced a transition to trading on the OTC market following a Nasdaq delisting. The report is signed by Director and Chief Financial Officer Rachel Yu on September 22, 2025.